NEW YORK — The biopharmaceutical maker Bristol-Myers Squibb Co. has reached an agreement to acquire clinical-stage biopharmaceutical company Inhibitex, Inc.
Bristol-Myers (NYSE: BMY), based in New York City, will pay approximately $2.5 billion for Inhibitex (NASDAQ: INHX), which is based in Alpharetta, Ga., outside of Atlanta. Bristol-Myers plans to purchase Inhibitex stock for $26 per share in cash. It will finance the deal using existing cash resources.
The acquisition gives Bristol-Myers, which employs about 420 people at a site in DeWitt, an antiviral drug Inhibitex is developing to treat the hepatitis C virus. That drug, INX-189, is in Phase II development.
(Sponsored)
Year-End Benefits Check: Is Your Team Getting the BOOST They Deserve for 2026?
As we close out 2025 and finalize employee benefits for the coming year, there’s one question every small to medium-sized business owner should ask: Are your employees truly understanding—and maximizing—the
Ask the Expert: How Registered Apprenticeship Can Solve Employers’ Workforce Challenges
In today’s tight labor market, finding and retaining skilled workers is tougher than ever. Many industries are facing talent shortages, rising turnover costs, and the pressure to keep pace with
“The acquisition of Inhibitex builds on Bristol-Myers Squibb’s long history of discovering, developing, and delivering innovative new medicines in virology and enriches our portfolio of investigational medicines for hepatitis C,” Bristol-Myers CEO Lamberto Andreotti said in a news release.
